Ozempic
Product Images NDC 0169-4136

Product Visual Gallery

This gallery contains 125 technical images submitted to the FDA as part of the official labeling for Ozempic (NDC 0169-4136). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novo Nordisk Pharmaceutical Industries, Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural_formula (Image 01)

Chemical structure of the active ingredient in Ozempic, showing its peptide chain and attached molecular groups in a detailed diagram.*

FDA Label Image

Figure 1. Mean 24-hour Plasma Glucose Profiles (Image 02)

A line graph depicting plasma glucose levels (mg/dL) over 24 hours following a breakfast meal. It compares four groups: OZEMPIC 0.68 mg, OZEMPIC 1 mg, placebo baseline, and placebo 1 mg, showing changes in glucose concentration measured at multiple time points after eating.*

FDA Label Image

Figure 2. Mean Insulin Secretion (Image 03)

A line graph depicting insulin secretion rate (pmol/kg/min) on the y-axis versus plasma glucose (mg/dL) on the x-axis, comparing different treatment groups including subjects treated with Ozempic (semaglutide) at baseline and at 1 mg end of treatment, placebo groups, and healthy subjects. The graph shows trends of insulin secretion changes across plasma glucose levels.*

FDA Label Image

Figure_3 (Image 04)

A chart showing relative exposure (average concentration) ratios and 90% confidence intervals for semaglutide by intrinsic factors including sex, age groups, race, ethnicity, body weight categories, and renal impairment levels. The graph compares exposure to a reference subject profile, indicating variations across these intrinsic factors.*

FDA Label Image

Figure 4. Impact Of Semaglutid (Image 05)

A data table presenting the relative exposure ratios and 90% confidence intervals for various co-administered medications with associated dosing recommendations. The table includes drugs such as Metformin, S-warfarin, R-warfarin, Digoxin, Atorvastatin, Ethinylestradiol, and Levonorgestrel, with a recommendation of no dose adjustment for all listed medications.*

FDA Label Image

Figure 5. Mean Hba1c (%) Over Time (Baseline to Week 56)

Instructional illustration showing a close-up of a hand twisting or removing the cap from a pen injector device, likely for Ozempic medication. The image depicts the proper way to hold and turn the pen cap before use.*

FDA Label Image

Figure_6 (Figure 6)

A Kaplan-Meier curve chart comparing the percentage of patients with an event over time from randomization (in weeks) between Ozempic and placebo groups. The chart shows lower event rates for Ozempic compared to placebo, with hazard ratio (HR) 0.74 and 95% confidence interval [0.58 - 0.95]. Patient counts at risk for both groups are listed at intervals along the x-axis.*

FDA Label Image

Figure_7 (Figure 7)

A Kaplan-Meier curve comparing the percentage of patients with an event over time from randomization (in months) for Ozempic versus placebo. The graph includes number of patients at risk at various time points and shows hazard ratio (HR) 0.76 with 95% confidence interval [0.66 - 0.88].*

FDA Label Image

Figure_8 (Figure 8)

A Kaplan-Meier curve chart comparing the percentage of patients with an event over time (in months) between Ozempic and placebo groups. The x-axis represents time from randomization in months; the y-axis represents the percent of patients with the event. Ozempic's curve shows a consistently lower event rate compared to placebo. A hazard ratio (HR) of 0.82 with a 95% confidence interval of 0.68 to 0.98 is noted. Numbers of patients at risk are listed below the graph for each time point.*

FDA Label Image

Figure_9 (Figure 9)

A line graph comparing the estimated glomerular filtration rate (eGFR in mL/min/1.73m2) over time in weeks between Ozempic and placebo groups. The Ozempic group shows a less steep decline in eGFR compared to the placebo group from randomization up to 104 weeks. Patient numbers at various time points are listed below the chart.*

FDA Label Image

Image_121 (Image 07)

Ozempic 1.34 mg/mL injection solution carton from Novo Nordisk Pharmaceutical Industries, LP. The packaging shows the brand name Ozempic prominently with the active ingredient strength stated as 1.34 mg/mL. The product is presented as a multi-dose pen for subcutaneous injection, with details on the quantity inside the box, which includes pens containing the medication. The label includes visual brand elements consistent with Novo Nordisk's design.*

FDA Label Image

Ozempic Pen And Parts (Image 08)

An instructional diagram of the Ozempic pen and NovoFine Plus needle showing parts and features labeled, including the pen cap, pen window, dose counter, dose pointer, dose selector, dose button, and expiration date location. The needle assembly is also broken down into outer needle cap, inner needle cap, needle, and paper tab. Additional dose guidance symbols are shown, such as the flow check symbol and dashed line used for dose guidance.*

FDA Label Image

Ozempic Dose Counter Closeup (Image 110)

An instructional illustration showing a close-up of a hand holding an injection pen. The hand is depicted removing or attaching a cap to the pen needle, indicated by an arrow pointing outward from the needle tip.*

FDA Label Image

Image_123 (Image 09)

An instructional illustration showing hands adjusting or assembling parts on a medical device, likely an injection pen, with a focus on twisting or turning a component to prepare the device for use.*

FDA Label Image

Image_124 (Image 10)

Instructional illustration showing a hand holding an Ozempic injection pen with the cap being removed, demonstrating the first step in preparing the injection device for use.*

FDA Label Image

Image_125 (Image 11)

An instructional diagram showing a close-up of two hands; one hand is holding a small vial or device while the other hand is positioned to remove a cap or cover by pulling it away in the indicated direction (to the left). The image appears to demonstrate the first step in preparing or using the product, likely related to Ozempic injection preparation.*

FDA Label Image

Image_126 (Image 12)

An instructional illustration depicting a hand holding a prefilled pen injector, preparing to administer an injection. The image highlights the connection or attachment of a needle to the pen device, emphasizing proper handling technique.*

FDA Label Image

Image_127 (Image 13)

An instructional illustration showing a person assembling or preparing a prefilled syringe, likely for injection. The hands are holding the syringe and a cap, demonstrating how to remove or attach the needle cover securely before use.*

FDA Label Image

Image_128 (Image 14)

An instructional illustration showing a syringe with a needle being connected to a vial, with arrows indicating the direction of connection, related to medication preparation or administration.*

FDA Label Image

Image_129 (Image 15)

Ozempic carton packaging for the injectable solution is shown with strengths of 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. The image depicts a box with the brand name Ozempic prominently displayed, along with the concentration and dosage form. The labeler name Novo Nordisk Pharmaceutical Industries, LP is visible.*

FDA Label Image

Image_flow_check_5 (Image 16)

Ozempic subcutaneous injection cartons in three strengths: 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. Each carton shows the Novo Nordisk pharmaceutical logo and labeler, Novo Nordisk Pharmaceutical Industries, LP. The packaging colors vary slightly between strengths but all are clearly branded as Ozempic.*

FDA Label Image

Image_130 (Image 17)

Instructional diagram showing a person performing a flow check on a pen-type injector. The illustration depicts pressing the button or plunger with the caption 'Flow check symbol selected' to ensure proper medication flow before injection.*

FDA Label Image

Image_131 (Image 18)

An instructional illustration depicting a hand holding a pen-like injector device with the cap being removed by pulling upward, indicated by a black arrow. This likely demonstrates preparation steps for using the injection device, associated with the Ozempic product from Novo Nordisk Pharmaceutical Industries, LP.*

FDA Label Image

Image_132 (Image 19)

The packaging label for Ozempic, available in strengths of 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL, presented as a multi-dose pen injector. The label includes the Novo Nordisk logo and highlights the medication name prominently on the front. The label also shows patient instructions and dosage information for use with the pen injector.*

FDA Label Image

Image_dose_counter_5 (Image 20)

The image shows three Ozempic prefilled pen cartridges at strengths of .68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. Each cartridge is labeled with the Ozempic brand name and strength. The labeler is Novo Nordisk Pharmaceutical Industries, LP.*

FDA Label Image

Image_133 (Image 21)

An instructional illustration showing a pen injector with a window display. The display shows a dotted line and '1 mg selected,' indicating how to select a dose of 1 mg on the pen.*

FDA Label Image

Image_134 (Image 22)

The image shows the Ozempic pen injector packaging label by Novo Nordisk Pharmaceutical Industries, containing 2.68 mg/mL solution for subcutaneous injection. The label features black and magenta text on a white background, with instructions for use depicted on the device image, including numbered steps and dosage adjustment markings.*

FDA Label Image

Image_135 (Image 23)

An instructional illustration showing a hand turning the dose counter stopper on a pen injector, indicating that one dose is left. This image demonstrates how to adjust or check the dose counter on the device.*

FDA Label Image

Image_136 (Image 24)

An instructional diagram depicting the recommended injection sites for Ozempic .68 mg/mL, 1.34 mg/mL, or 2.68 mg/mL. The front and back of a human torso are shown, highlighting possible abdominal and thigh injection areas, as well as the upper arm, illustrating where the medication may be administered.*

FDA Label Image

Image_137 (Image 25)

An instructional illustration showing a hand holding a pen-like injection device with the other hand pulling down a blue cap or cover, indicated by a downward arrow. The image likely demonstrates the first step to prepare or use the injectable pen device.*

FDA Label Image

Image_138 (Image 26)

An instructional illustration showing a hand holding and preparing a pen injector device for use. The diagram includes a close-up view of the pen tip and an arrow indicating the direction to attach or remove a needle. The image is related to the Ozempic injection pen for subcutaneous administration.*

FDA Label Image

Image_139 (Image 27)

An instructional illustration showing a hand holding a syringe or pen device with a speech bubble instructing to 'Count slowly: 1-2-3-4-5-6,' indicating a step in an administration process or dosage timing.*

FDA Label Image

Image_140 (Image 28)

An instructional illustration showing a pen injector device with an arrow pointing upward, indicating the step of removing or lifting the cap from the pen. No text is visible. The image visually guides users on how to begin preparing the pen for use, associated with the Ozempic medication by Novo Nordisk.*

FDA Label Image

Image_141 (Image 29)

The image shows the carton for Ozempic injection in 2.68 mg/mL strength. The packaging includes the brand name Ozempic, the concentration 2.68 mg/mL, and dosing information for injection use. It is manufactured by Novo Nordisk Pharmaceutical Industries, LP. The label features color-coded design elements and clearly states dosage in a pre-filled pen format.*

FDA Label Image

Image_142 (Image 30)

An instructional diagram showing a hand holding an Ozempic injection pen with the cap being removed by pulling it upwards. A blue arrow indicates the direction to pull the cap off the pen before use.*

FDA Label Image

Image_143 (Image 31)

An instructional diagram illustrating the process of preparing or opening a medication vial. The image shows a vial with its protective top and an arrow indicating the removal or attachment action with a cap or tool above the vial.*

FDA Label Image

Image_144 (Image 32)

An instructional illustration showing a close-up of hands preparing an injection pen. It depicts one hand holding the pen while the other hand is peeling off a protective cap or seal from the needle area, demonstrating a step in the injection preparation process.*

FDA Label Image

Image_145 (Image 33)

An instructional diagram showing two arrows pointing towards an injection pen device cap, illustrating the action of attaching or removing the cap. This image relates to the use or handling of the injection device, likely for Ozempic.*

FDA Label Image

Image_146 (Image 34)

Ozempic cartridge pen labels showing strengths 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. Each label displays the proprietary name Ozempic, the strength in mg/mL, and the labeler Novo Nordisk Pharmaceutical Industries, LP. The labels are white with purple accents and include distinguishable numeric strength indicators.*

FDA Label Image

Image_147 (Image 35)

Ozempic multi-dose pen labels showing strengths of 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. Each label states the proprietary name Ozempic and the concentrations clearly. The labels are primarily orange and white and include the Novo Nordisk Pharmaceutical Industries, LP name as the labeler.*

FDA Label Image

Image_148 (Image 36)

FDA Label Image

Image_149 (Image 37)

FDA Label Image

Image_61 (Image 06)

A line graph comparing HbA1c percentages over weeks post-randomization for Ozempic 0.5 mg, Ozempic 1 mg, and Sitagliptin. The x-axis represents weeks from 0 to 56, and the y-axis shows HbA1c percentages from about 6.0 to 8.5%. The graph includes patient counts for each treatment over time, illustrating changes in HbA1c levels with error bars at week 56.*

FDA Label Image

Image 62 Ozempic Pen (Image 38)

Packaging label for Ozempic, featuring three separate panels for the strengths 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. Each panel shows the proprietary name Ozempic, the concentration in mg/mL, and the labeler Novo Nordisk Pharmaceutical Industries, LP. The label layout includes dosage form and packaging details and a barcode on the right side.*

FDA Label Image

Image 62 Ozempic Dose Counter (Image 111)

Illustration showing how to check the flow symbol on the Ozempic injection pen. The image depicts hands holding the pen with an arrow indicating the flow check symbol is selected, signifying proper flow before injection.*

FDA Label Image

Image_63 (Image 39)

An instructional diagram showing the components and features of the Ozempic pen and NovoFine Plus needle. It labels parts including the pen cap, pen window, dose counter, dose pointer, dose selector, and dose button on the pen, as well as the outer needle cap, inner needle cap, needle, and paper tab of the needle. The diagram also highlights the flow check symbol and dashed line used for dose guidance.*

FDA Label Image

Image_64 (Image 40)

An instructional illustration showing hands manipulating a pen-style injector, likely for the medication Ozempic. The image appears to demonstrate how to remove or adjust a part of the injector device, possibly the needle or cap, as part of medication preparation or administration.*

FDA Label Image

Image_65 (Image 41)

An instructional illustration showing a hand holding an injectable pen device with the cap being removed or attached. This image likely depicts a step in the use or preparation of the Ozempic injectable pen by Novo Nordisk Pharmaceutical Industries, LP.*

FDA Label Image

Image_66 (Image 42)

An instructional diagram showing a hand holding and preparing a medical injection pen, with an arrow indicating a step of pulling or pushing on the pen's end. The image is a step in using the Ozempic pen injection device.*

FDA Label Image

Image_67 (Image 43)

Illustration showing a hand holding the Ozempic pen injector near the needle area, demonstrating the action of attaching or securing the needle to the pen device. The image highlights proper handling technique for assembling the injector pen before use.*

FDA Label Image

Image_68 (Image 44)

An instructional illustration showing a hand attaching a needle or pen tip to an injection device, with a protective cover being removed. This image is likely part of the usage directions for Ozempic injection pens by Novo Nordisk Pharmaceutical Industries, LP.*

FDA Label Image

Image_69 (Image 45)

An instructional illustration showing the preparation of a medication injection. The image depicts an injection pen with a protective cap being removed by a hand, indicating a step in medication administration for products like Ozempic.*

FDA Label Image

Image_flow_check_3 (Image 46)

Packaging label for Ozempic injectable solution in a 2 mL single-dose prefilled pen, containing 1.34 mg/mL of the active ingredient. The label shows Novo Nordisk Pharmaceutical Industries, LP as the labeler and includes storage and usage instructions. The pen is orange colored with a clear dosing display window.*

FDA Label Image

Image_70 (Image 47)

Ozempic injectable solution in a 0.68 mg/mL strength is displayed on the packaging label. The label highlights the brand name Ozempic, the concentration of 0.68 mg/mL, and the labeler Novo Nordisk Pharmaceutical Industries, LP. The packaging is primarily orange with white and gray sections, and includes a depiction of the drug vial and pen injector.*

FDA Label Image

Image_71 (Image 48)

Instructional illustration showing a finger pressing a flow check feature on a device, with a displayed flow check symbol indicating selection. This diagram assists with proper operation of a medication delivery device related to Ozempic provided by Novo Nordisk.*

FDA Label Image

Image_72 (Image 49)

Illustration showing a hand holding a pen-like injector device, presumably a medication injector. The illustration indicates to remove the blue cap by pulling it upwards, as shown by a large arrow. A small cap is shown detached and held above the main device.*

FDA Label Image

Iimage_dose_counter_3 (Image 50)

Packaging label for Ozempic in a 0.68 mg/mL dosage form. The label prominently displays the proprietary name Ozempic along with its strength and manufacturer, Novo Nordisk Pharmaceutical Industries, LP. This is a solution for injection, clearly marked on the label, suitable for patient use.*

FDA Label Image

Image_73 (Image 51)

Ozempic 2.68 mg/mL solution in a prefilled pen cartridge label from Novo Nordisk Pharmaceutical Industries, LP. The clear plastic cartridge shows dosing marks and contains a visible orange-yellow solution. The cartridge is part of a pen injection device designed for subcutaneous use.*

FDA Label Image

Image_74 (Image 52)

An instructional diagram illustrating how to set the dosage on a pen injector device. It shows a close-up of the dose selector with a dotted line example selecting 0.25 mg and an arrow pointing to the dial mechanism, indicating the user can turn the dial to select the desired dose, such as 0.5 mg.*

FDA Label Image

Image_75 (Image 53)

The image shows the label of Ozempic, a 2.68 mg/mL injectable solution. The product name Ozempic, concentration 2.68 mg/mL, and dosage form as an injectable solution are visible. The label includes Novo Nordisk Pharmaceutical Industries, LP as the labeler. Additional graphical elements and barcodes are present on the label.*

FDA Label Image

Image_76 (Image 54)

An instructional diagram showing hands holding and using a dose counter pen device labeled 'Ozempic'. The display on the pen shows a numeric dose setting, with an example dose of 0.25 mg highlighted, demonstrating dose selection or adjustment for Ozempic injectable solution.*

FDA Label Image

Image_77 (Image 55)

An instructional illustration showing front and back views of a human torso with four designated injection sites marked on the abdomen and thighs, typically used for subcutaneous injection guidance.*

FDA Label Image

Image_78 (Image 56)

An instructional illustration showing a hand holding a pen-like injection device vertically against the abdomen. A downward arrow indicates the direction to press the device against the skin for injection.*

FDA Label Image

Image_79 (Image 57)

An instructional diagram showing a hand holding a pen-like injection device with a needle exposed, illustrating the proper technique for administering an injection. This image is associated with Ozempic, a medication by Novo Nordisk Pharmaceutical Industries, LP, available in strengths 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL.*

FDA Label Image

Image_80 (Image 58)

An instructional illustration showing a hand holding a pen-like injector device with the text bubble 'Count slowly: 1-2-3-4-5-6,' suggesting a step for slow counting during use.*

FDA Label Image

Image_81 (Image 59)

An instructional diagram showing a pen injector with an arrow pointing upward, indicating the action to remove the cap from the device before use.*

FDA Label Image

Image_82 (Image 60)

Ozempic injection carton and vial labels showing strengths of 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL of the active ingredient in a prefilled pen device. The labeler is Novo Nordisk Pharmaceutical Industries, LP. The packaging displays the product name and strength prominently in blue and pink text on a white background.*

FDA Label Image

Image_83 (Image 61)

An instructional illustration showing a hand twisting off the blue cap of a pen injector device, demonstrating how to prepare the device for use.*

FDA Label Image

Image_84 (Image 62)

An instructional illustration showing the step of inserting a pen needle onto a medication pen. The image features a hand holding a small pen needle above a pen device, with an arrow indicating the needle should be pushed downward onto the pen.*

FDA Label Image

Image_85 (Image 63)

Illustration showing hands preparing an injection pen, specifically demonstrating removal of the protective cap from the needle. The image is instructional, related to the administration of Ozempic injection pen by Novo Nordisk.*

FDA Label Image

Image_86 (Image 64)

An instructional diagram showing the disassembly of a pen device, possibly for Ozempic injection. The image depicts the removal of the pen cap by pulling it away from the pen body, indicated by directional arrows.*

FDA Label Image

Image_87 (Image 65)

Packaging label for Ozempic 1.34 mg/mL, a solution for injection in a 3 mL pre-filled pen. The label shows Novo Nordisk Pharmaceutical Industries, LP as the manufacturer and includes detailed usage instructions and product information on the pen.*

FDA Label Image

Image_88 (Image 66)

Ozempic 2.68 mg/mL injection cartridge carton from Novo Nordisk Pharmaceutical Industries, LP. The label shows the proprietary name Ozempic and strength 2.68 mg/mL, indicating it is a pre-filled pen or cartridge dosage form. Packaging includes branding and regulatory information.*

FDA Label Image

Image_89 (Image 67)

FDA Label Image

Image_91 (Image 73)

Ozempic injection vial label displaying available concentrations 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. The label includes the Novo Nordisk logo and specifies the product as an injectable solution in a glass vial. Manufacturer listed as Novo Nordisk Pharmaceutical Industries, LP.*

FDA Label Image

Image 92 Ozempic Pen (Image 74)

Illustration of the Ozempic pen and needle components, showing labeled parts including pen cap, pen window, expiration date on the back, dose counter, dose pointer, dose selector, and dose button. Needle parts include outer needle cap, inner needle cap, needle, and paper tab.*

FDA Label Image

Image 92 Ozempic Dose Counter (Image 112)

Illustration showing a hand adjusting the dose selector on an Ozempic injection pen. The pen is partially visible with a blue body and a clear section for medication, demonstrating the proper way to set or change the dose before administration.*

FDA Label Image

Image_93 (Image 75)

Illustration showing a step in the use or assembly of a device, featuring hands gripping and manipulating a small cylindrical component. The image is likely part of instructions for Ozempic injection device preparation or administration.*

FDA Label Image

Image_94 (Image 76)

An illustration showing a close-up view of a hand holding a pen injector device, focusing on the injection end of the device. The image appears instructional, likely demonstrating use of the pen for drug administration.*

FDA Label Image

Image_95 (Image 77)

Illustration depicting a step in using the Ozempic injection pen, showing a hand pulling off or twisting the pen cap to prepare the device for injection.*

FDA Label Image

Image_96 (Image 78)

An instructional illustration showing a close-up of a hand holding and preparing a blue Ozempic pen injector, focusing on the thumb and forefinger gripping the cap for removal or attachment, with a stylized figure head in the background for guidance context.*

FDA Label Image

Image_97 (Image 79)

An instructional illustration showing a hand inserting or aligning a cap or protective cover onto the tip of a pen device, with an arrow indicating the direction for attachment. This likely pertains to the use or preparation of the Ozempic injection pen.*

FDA Label Image

Image_98 (Image 80)

An instructional illustration showing a hand removing the protective cap from the tip of a pen injector device. The image includes an arrow indicating the direction to pull the cap off.*

FDA Label Image

Image_99 (Image 81)

Ozempic injectable solution packaging label showing available strengths of 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. The label includes the product name 'Ozempic' prominently, with the labeler listed as Novo Nordisk Pharmaceutical Industries, LP.*

FDA Label Image

Image_flow_check_4 (Image 82)

Packaging label of Ozempic with strengths 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. The label shows a pen device for subcutaneous injection. The product is labeled by Novo Nordisk Pharmaceutical Industries, LP, indicating it is a prescription injectable medication.*

FDA Label Image

Image_100 (Image 83)

An instructional illustration showing hands holding an Ozempic pen injector with the flow check symbol displayed on the injection window, indicating the flow check feature selection. The image includes a close-up of the flow check symbol and an arrow pointing upward toward the symbol on the pen.*

FDA Label Image

Image_101 (Image 84)

An instructional illustration showing a hand holding an Ozempic pen injector with a close-up of the pen cap. The image indicates a user action to rotate or pull the cap upward to remove it, likely demonstrating first step usage of the Ozempic injection pen.*

FDA Label Image

Image_102 (Image 85)

Ozempic injection vial with strength 2.68 mg/mL. The label shows the brand name Ozempic, active ingredient concentration, and volume. The product is manufactured by Novo Nordisk Pharmaceutical Industries, LP. The vial has a clear appearance with purple accents on the label and purple cap.*

FDA Label Image

Image_dose_counter_4 (Image 86)

Packaging label for Ozempic injection showing available strengths of 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. The label includes the product name Ozempic and is produced by Novo Nordisk Pharmaceutical Industries, LP.*

FDA Label Image

Image_103 (Image 87)

An instructional illustration showing how to select the dose on an Ozempic injection pen. The image highlights a dashed line indicator and the number "2 mg" to show the selected dose setting.*

FDA Label Image

Image_104 (Image 88)

Ozempic prefilled pen carton showing the Novo Nordisk Pharmaceutical Industries, LP labeler. The packaging includes multi-language text and displays strengths of 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL of the product, which is an injectable solution. The carton is mainly white with design elements in pink and purple.*

FDA Label Image

Image_105 (Image 89)

Instructional illustration showing a close-up of the Ozempic injection pen dose counter. The image highlights the dose counter stopping at 2 mg left, indicating the remaining dose. The illustration uses a hand pointing to the dose counter with accompanying text explaining that the dose counter has stopped with 2 mg left.*

FDA Label Image

Image_106 (Image 90)

An instructional anatomical illustration showing the front and back views of a human torso, likely indicating injection sites or areas for medication administration.*

FDA Label Image

Image_107 (Image 91)

An instructional illustration showing a hand holding a pen-like injector device vertically with the needle end pointing downward. A downward arrow below the device indicates the direction for injection or positioning, suggesting an injection step for the Ozempic product.*

FDA Label Image

Image_108 (Image 92)

An instructional diagram showing the priming process for an Ozempic injection pen. It illustrates holding the pen upright, attaching a needle, dialing to 0 mg, and pressing the dose button until a drop of liquid appears at the needle tip, indicating readiness for injection.*

FDA Label Image

Image_109 (Image 93)

Instructional illustration showing a hand holding an Ozempic injection pen upright, with a speech bubble instructing to count slowly from 1 to 6. The image appears to guide users on proper injection timing or dosage administration steps.*

FDA Label Image

Image_110 (Image 94)

An instructional illustration showing the end of a pen injector with an arrow pointing upward, likely indicating a step to remove or pull off a cap or protective cover from the device.*

FDA Label Image

Image_111 (Image 95)

Ozempic 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL injectable solution carton from Novo Nordisk Pharmaceutical Industries, LP. The front displays the Ozempic brand name and the concentration strengths clearly, along with the labeler information.*

FDA Label Image

Image_112 (Image 96)

An instructional illustration showing a hand gripping the cap of a pen-like device and rotating the cap counterclockwise, indicated by an arrow pointing left, demonstrating how to remove the cap from the device.*

FDA Label Image

Image_113 (Image 97)

An instructional illustration showing a syringe needle being inserted through a sealed vial stopper, indicating the process of drawing medication from the vial.*

FDA Label Image

Image_114 (Image 98)

An instructional illustration showing a close-up of two hands holding a pen-type injector device for Ozempic. The image demonstrates twisting or turning a part of the injector, indicated by a curved arrow, likely as part of the preparation or usage steps for the medication pen.*

FDA Label Image

Image_115 (Image 99)

An instructional illustration showing a close-up of a pen injector with an arrow pointing to a needle cap being removed, indicating the proper step to detach the needle cover from the pen before use.*

FDA Label Image

Image_116 (Image 100)

The image shows the packaging label for Ozempic, a product by Novo Nordisk Pharmaceutical Industries, LP. The label indicates available strengths of 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. The packaging is primarily white with purple and orange accents, including the Novo Nordisk logo.*

FDA Label Image

Image_117 (Image 101)

Ozempic injection vial label showing dose strengths of 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. The label includes the proprietary name Ozempic and indicates it is manufactured by Novo Nordisk Pharmaceutical Industries, LP. The design displays dosing and product identification details on a blue and white background.*

FDA Label Image

Image_118 (Image 104)

An instructional diagram showing components of the Ozempic pen and NovoFine Plus needle. It illustrates the pen cap, pen window, expiration date label location, dose counter, dose pointer, dose selector, and dose button on the Ozempic pen. Separately, it shows parts of the needle including outer needle cap, inner needle cap, needle, and paper tab, with flow check symbols and a dashed line for dose guidance.*

FDA Label Image

Image_119 (Image 105)

An instructional illustration showing hands holding a pen-like device with an arrow indicating the removal of a cap or cover. This image is likely part of a usage or preparation guide for a medical injection device.*

FDA Label Image

Ifu Mpfs Before Use (Before After)

An instructional illustration titled 'Before use' showing the parts of a prefilled syringe for Ozempic. The syringe components labeled include needle cap, label, glass barrel containing medicine, plunger, and plunger rod, detailing the syringe setup before administration.*

FDA Label Image

Ifu Mpfs After Use (2. Ifu Mpfs After Use.jpg)

An instructional illustration showing the Ozempic injection pen after use. The image highlights the plunger position, indicating the injection is complete. The pen is shown horizontally with the needle attached on the left side.*

FDA Label Image

Not Included In Your Carton (Image 68)

An instructional illustration showing three items used in injection safety and disposal: an alcohol wipe in a sealed square packet, a cotton ball, and a sharps disposal container with a secure lid.*

FDA Label Image

Step 1 Take One Prefilled Syringe (Image 109)

Illustration showing the connection process of a pen needle to an injection device, with a hand holding the needle cap and an arrow indicating the direction to attach it.*

FDA Label Image

Step-2 (Step 2)

An instructional illustration showing the Ozempic injection pen, highlighting the medicine reservoir inside the pen and a labeled expiration date on the side in the format YYYY-MM-DD. The visual includes an arrow pointing to the medicine compartment within the pen.*

FDA Label Image

Choose Your Injection Site (Image 71)

Instructional diagram showing recommended injection sites for Ozempic, including the stomach area or thighs, and the back of the upper arm, which should only be used with help from someone else. An inset image illustrates a hand injecting into the stomach area.*

FDA Label Image

Step 4: Pull Off The Needle Cap (Image 102)

Packaging label for Ozempic (semaglutide) injection prefilled pen, 2.68 mg/mL strength, by Novo Nordisk Pharmaceutical Industries, LP. The label indicates single patient use, subcutaneous injection, and dosage increments of 2 mg. The design shows the pen device image, dosing instructions, and company logo on a white and gold background.*

FDA Label Image

Step 5: Insert Your Prefilled Syringe (Image 103)

Packaging label for Ozempic (semaglutide) injection 1 mg in a 4 mg/mL (1.34 mg/mL) prefilled pen. The label indicates single patient use only and delivery in 1 mg increments. It is a subcutaneous injection pen from Novo Nordisk Pharmaceutical Industries, LP. The label also shows the pen image and includes usage instructions with a schedule for weekly injections.*

FDA Label Image

Step 6 Inject Your Dose (Image 106)

An instructional illustration showing a hand holding a pen-like injector device with a visible cartridge inside. The device has a blue cap or portion on the left side and a grey tip on the right side. The illustration is labeled with a letter "B" in the upper left corner.*

FDA Label Image

Step 7 Remove Your Syringe (Image 107)

An instructional illustration showing a person’s hands removing a protective cap from the tip of an Ozempic injection pen. The image highlights the proper technique for cap removal, indicated by an arrow pointing away from the pen tip.*

FDA Label Image

Step-8 (Step 8)

An instructional illustration showing a hand holding a syringe above a vial with a septum top, indicating the action of inserting the needle into the vial. This image likely demonstrates how to prepare or draw medication from the vial.*

FDA Label Image

Image_155 (Image 69)

Ozempic (semaglutide) injection 0.68 mg/mL prefilled pen packaging label showing available strengths 0.25 mg and 0.5 mg doses, intended for single patient use. The label highlights the product is for subcutaneous use once weekly, includes a prefilled pen image, and states it is manufactured by Novo Nordisk Pharmaceutical Industries, LP.*

FDA Label Image

Image_153 (Image 70)

Packaging label for Ozempic (semaglutide) injection 1 mg strength. The label states it is a 4 mg/mL (1.34 mg/mL) prefilled pen for subcutaneous use only, delivering doses in 1 mg increments once weekly. The label includes usage instructions, product components, and the Novo Nordisk Pharmaceutical Industries, LP labeler information.*

FDA Label Image

Image_154 (Image 72)

Packaging label for Ozempic (semaglutide) injection 2.68 mg/mL prefilled pen by Novo Nordisk. The label indicates dosing in 2 mg increments for single patient use only, specifying subcutaneous injection once weekly. The label features Novo Nordisk branding and illustrations of the prefilled pen and cap, with instructions to use Ozempic once weekly and space to record injection days.*

FDA Label Image

1.5_ml_carton (Dual Dose 1.5 mL Carton.jpg)

Packaging label for Ozempic (semaglutide) injection, 2 mg/1.5 mL (1.34 mg/mL) prefilled pen by Novo Nordisk Pharmaceutical Industries, LP. The box includes dose options of 0.25 mg and 0.5 mg increments per injection. It is for single patient use only and designed for subcutaneous use once weekly. The package contains one pen, six NovoFine Plus 32G needles, and product literature.*

FDA Label Image

1mg-1.5ml_carton (1 mg 1.5 mL Carton.jpg)

Ozempic 1 mg (semaglutide) injection prefilled pen carton label showing 2 pens, each delivering 1 mg doses in 1 mg increments only. The label indicates 2 mg/1.5 mL (1.34 mg/mL) strength, for single patient use only, with subcutaneous administration once weekly. Novo Nordisk is the labeler, and the packaging includes product images, dosing instructions, and a note to dispense the Medication Guide.*

FDA Label Image

Package/label Display Panel – 0.25 mg/0.5 mL – Syringe (0.25mg Carton.jpg)

Packaging label for Ozempic 0.25 mg/0.5 mL (semaglutide) injection by Novo Nordisk Pharmaceutical Industries, LP. The carton contains 4 single-dose prefilled syringes with 0.25 mg semaglutide per 0.5 mL. The label notes subcutaneous use only and weekly dosing. The label also includes usage instructions and a medication guide dispense statement.*

FDA Label Image

Package/label Display Panel – 0.5 mg/0.5 mL – Syringe (0.5mg Carton.jpg)

Ozempic 0.5 mg/0.5 mL (semaglutide) injection prefilled syringes carton by Novo Nordisk Pharmaceutical Industries, LP. The package contains 4 single-dose 0.5 mL prefilled syringes. Label highlights use of Ozempic one time a week for subcutaneous injection. Packaging includes images of the injection syringes and instructions to dispense the enclosed Medication Guide.*

FDA Label Image

Package/label Display Panel – 1 mg/0.5 mL – Syringe (1mg Carton)

Packaging label for Ozempic (semaglutide) injection 1 mg/0.5 mL by Novo Nordisk Pharmaceutical Industries, LP. The carton includes 4 single-dose prefilled syringes, each delivering 1 mg semaglutide in 0.5 mL. Directions indicate use once weekly subcutaneously. The label displays the product name, strength, dosage form, quantity, and manufacturer information along with usage instructions and support website.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.